steatohepatitis
fatty liver

Foreman suggests steatohepatitis and House agrees to treat for it.

Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.

Obesity has emerged as an important risk factor as it can lead to steatohepatitis.

Steatohepatitis is an advanced stage of fatty liver disease.

This substitution has also been linked to increased frequency of non-alcoholic steatohepatitis.

A study in a dietary model of nonalcoholic steatohepatitis in rats.

Non-alcoholic steatohepatitis is fatty liver disease due to causes other than alcohol.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis.

Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.

It is likely to have different pathogenesis than non-alcoholic steatohepatitis which is a diffuse process.

Early on, there is steatosis, which can evolve to steatohepatitis and eventually to cholestasis of varying severity.

A trip to a doctor found Shanae had non-alcoholic steatohepatitis - a fatty liver - as a result of her weight.

Christian Lavallee will be studying the cellular and molecular mechanisms leading to non-alcoholic steatohepatitis.

To the team's surprise, they realized that the mice were in fact in the advanced stages of nonalcoholic steatohepatitis.

Ballooning degeneration - another histopathologic finding of steatohepatitis.

Sometimes it progresses to a form of liver inflammation called steatohepatitis, which in turn can progress to full-blown cirrhosis.

Other potential hepatobiliary dysfunctions include steatosis, steatohepatitis, cholestasis, and cholelithiasis.

The other 20% will develop a disease called nonalcoholic steatohepatitis, or NASH.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Pioglitazone has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental.

Liver disease called nonalcoholic steatohepatitis.

According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis.

Nonalcoholic steatohepatitis (if progression to cirrhosis has occurred)

Some evidence suggests that taking melatonin improves markers of liver function in the blood of people with nonalcoholic steatohepatitis.